Automate Your Wheel Strategy on MDT
With Tiblio's Option Bot, you can configure your own wheel strategy including MDT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDT
- Rev/Share 27.1166
- Book/Share 38.1159
- PB 2.5746
- Debt/Equity 0.5981
- CurrentRatio 2.4153
- ROIC 0.0631
- MktCap 125337240015.0
- FreeCF/Share 4.0615
- PFCF 24.0755
- PE 26.287
- Debt/Assets 0.3186
- DivYield 0.0289
- ROE 0.0983
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MDT | Goldman | Sell | Neutral | -- | $111 | Nov. 19, 2025 |
| Upgrade | MDT | Wolfe Research | Underperform | Peer Perform | -- | -- | June 30, 2025 |
| Initiation | MDT | Leerink Partners | -- | Outperform | -- | $110 | June 16, 2025 |
| Upgrade | MDT | Citigroup | Neutral | Buy | $92 | $107 | March 4, 2025 |
| Upgrade | MDT | RBC Capital Mkts | Sector Perform | Outperform | $98 | $105 | Oct. 10, 2024 |
| Reiterated | MDT | Oppenheimer | -- | Perform | $92 | $94 | Aug. 21, 2024 |
News
Build a Stronger 2026 Portfolio With These 5 Dividend Aristocrats
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ATO, MDT, PEP, CAT and SPGI stand out as dividend aristocrats for 2026, offering decades of hikes, solid yields and defensive income.
Read More
Medtronic (MDT) Upgraded to Buy: Here's Why
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic (MDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
MDT or ESLOY: Which Is the Better Value Stock Right Now?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
MDT Stock Set to Benefit From the FDA Clearance of Hugo RAS System
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic gains from the FDA clearance of its Hugo RAS system, expanding U.S. access to robotic-assisted urologic surgery.
Read More
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.
Read More
Robotics can 'democratize good healthcare' worldwide: Medtronic CEO
Published: November 27, 2025 by: Fox Business
Sentiment: Positive
Medtronic Chairman and CEO Geoffrey Martha discusses the company's latest robotic innovation and how robotics can impact healthcare on 'The Claman Countdown.' #fox #media #us #usa #new #news #foxbusiness #medtronic #robotics #technology #healthcare #medical #innovation #science #global #economy #business #ai #future #engineering #automation #medicine #healthtech
Read More
ISRG vs. MDT: A High-Tech Robotics Faceoff in the Race for Leadership
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Intuitive Surgical's robotics surge and Medtronic's broad innovation push set the stage for a high-tech showdown in next-gen minimally invasive care.
Read More
5 Must-Own Dividend Aristocrats That Can Weather a Coming Big Sell-Off
Published: November 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
The recent high-velocity sell-off may be a preview of what's to come this year or in 2026.
Read More
Medtronic plc (MDT) Q2 2026 Earnings Call Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Medtronic plc ( MDT ) Q2 2026 Earnings Call November 18, 2025 8:00 AM EST Company Participants Ryan Weispfenning - VP & Head of Investor Relations Geoffrey Martha - Chairman of the Board & CEO Thierry Pieton - Executive VP & CFO Laura Mauri - Senior VP and Chief Scientific & Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Travis Steed - BofA Securities, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Shagun Singh Chadha …
Read More
Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.
Read More
Medtronic (MDT) Q2 Earnings and Revenues Top Estimates
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic (MDT) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.26 per share a year ago.
Read More
Medtronic Lifts Outlook as Quarterly Profit, Sales Rise
Published: November 18, 2025 by: WSJ
Sentiment: Positive
Medtronic raised its fiscal-year outlook after logging higher profit and sales in its latest quarter, boosted by robust demand across end markets and healthy procedure volumes.
Read More
Medtronic Stock Rises After Earnings. What Caught Investors' Attention.
Published: November 18, 2025 by: Barrons
Sentiment: Positive
Medtronic exceeds fiscal second-quarter earnings and revenue expectations.
Read More
Medtronic beats second-quarter estimates on strength in heart devices segment
Published: November 18, 2025 by: Reuters
Sentiment: Positive
Medical device maker Medtronic topped Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its heart disease and diabetes devices.
Read More
Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland , Nov. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points above guidance midpoint GAAP diluted EPS of $1.07 increased 8%; non-GAAP diluted EPS of $1.36 increased 8%, above guidance Raising FY26 guidance: 5.5% organic revenue growth, …
Read More
Stay Ahead of the Game With Medtronic (MDT) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended October 2025.
Read More
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences.
Read More
Three-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions
Published: October 26, 2025 by: PRNewsWire
Sentiment: Neutral
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland , Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity™ Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as …
Read More
Medtronic: A Revitalized Dividend Aristocrat To Buy Now
Published: October 26, 2025 by: Seeking Alpha
Sentiment: Positive
Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive opportunity in the underpenetrated urge urinary incontinence market. Medtronic possesses an A S&P credit rating with a stable outlook.
Read More
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
5 Dividend Aristocrats Are Perfect for Boomers Seeking Growth and Income
Published: October 15, 2025 by: 24/7 Wall Street
Sentiment: Positive
While reaching retirement age can be both a blessing and a curse, relying on the U.S.
Read More
Why Medtronic (MDT) is a Top Value Stock for the Long-Term
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Medtronic plc - Special Call
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Medtronic plc - Special Call Company Participants Ryan Weispfenning - VP & Head of Investor Relations Emily Elswick Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Shagun Singh Chadha - RBC Capital Markets, Research Division Michael Polark - Wolfe Research, LLC Danielle Antalffy Presentation Ryan Weispfenning VP & Head of Investor Relations Okay. Hello, everyone.
Read More
Here's Why Medtronic (MDT) is a Strong Value Stock
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Medtronic plc (MDT) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Medtronic plc (NYSE:MDT ) Bank of America Global Healthcare Conference 2025 September 24, 2025 9:10 AM EDT Company Participants Thierry Pieton - Executive VP & CFO Presentation Unknown Analyst We're glad to have the Medtronic CFO, Thierry Pieton, here with us. So welcome.
Read More
Medtronic Receives FDA Nod for Altaviva Device: Stock to Gain?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
MDT gains FDA approval for its Altaviva device, a minimally invasive bladder control therapy with long-lasting benefits.
Read More
Medtronic (MDT) Up 1.5% Since Last Earnings Report: Can It Continue?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Read More
Medtronic: Buy This Dividend Aristocrat While It's Good Value
Published: September 17, 2025 by: Seeking Alpha
Sentiment: Positive
Medtronic remains a Buy for long-term investors, offering steady growth, durable income, and an attractive valuation below historical averages. MDT delivered solid fiscal Q1 2026 results, with 8.4% revenue growth and standout performance in Cardiac Ablation and Diabetes segments. The upcoming diabetes segment spinoff is expected to improve operating margins and reinforce MDT's growth trajectory.
Read More
1 Reason Every Investor Should Know About Medtronic (MDT)
Published: September 17, 2025 by: The Motley Fool
Sentiment: Neutral
The list of Dividend Kings -- the very few U.S.-traded stocks that have enacted dividend raises at least once annually for a minimum of 50 years in a row -- is extremely short. That's why it's quite an event when a new stock joins this very limited and exclusive club.
Read More
Medtronic initiates global pivotal study of cardiac pacing in a new patient population
Published: September 15, 2025 by: PRNewsWire
Sentiment: Neutral
Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today GALWAY, Ireland , Sept. 15, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for the treatment of patients with Heart Failure with preserved Ejection Fraction (ELEVATE-HFpEF, NCT06678841).
Read More
About Medtronic plc (MDT)
- IPO Date 1973-05-02
- Website https://www.medtronic.com
- Industry Medical - Devices
- CEO Geoffrey Straub Martha
- Employees 95000